A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

NCT04879849 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Triple Negative Breast Neoplasms
Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: Pembrolizumab
DRUG: TAK-676
RADIATION: Image-guided radiation therapy

Sponsor

Takeda